Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

Lymphoma Leukemia Clinical Trial

Official title:
Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

Status Completed

Clinical Trial Summary

B cell malignancies comprise a heterogeneous group of neoplasms including a vast majority of non-Hodgkin's lymphomas (NHL), lymphoblastic leukemias (ALL) and chronic lymphocytic leukemias (CLL). Current treatments for B cell malignancies include chemotherapy, radiation therapy, bone marrow transplantation, and peripheral blood stem cell transplantation. Despite these treatment modalities, most patients will remain incurable. Welgenaleucel (UWC19) is a CD19-directed genetically-modified autologous immunotherapy. This study is designed to evaluate safety and feasibility of administering Welgenaleucel (UWC19) transduced with anti-CD19 lentiviral vector to patients with advanced refractory hematologic malignancies, including DLBCL and ALL.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03811457
Study type	Interventional
Source	UWELL Biopharma
Contact
Status	Completed
Phase	N/A
Start date	June 1, 2017
Completion date	December 31, 2018

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05114837` - Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL	Phase 1/Phase 2
	Not yet recruiting	`NCT03975205` - To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames	Early Phase 1